Swissmedic's statement on how to handle discrepancies between EU and PIC/S GMP
Recommendation

16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
According to the Medicinal Products Licensing Ordinance (MPLO), the requirements as per EU GMP and the GMP guidelines of PIC/S are both valid in Switzerland. The Swiss Institute for Therapeutic Products ("Swissmedic") has now published a short statement on how to handle differences between the different GMP guidelines.
Generally, the compliance with both sets of guidelines is expected; in cases of discrepancies between the guidelines, the more stringent requirement applies. While the requirements are the same in most cases, they are not completely identical. Since a general harmonisation between both regulations is pursued, however, it has so far been accepted if the requirements of the PIC/S GMP guideline only were met for a short period of time until the requirements of the other guideline were added or updated. This practice, which had so far been tolerated, is now no longer accepted. The reason therefore is that the EU GMP guidelines usually enter into force earlier than the ones of PIC/S GMP. As an example, Swissmedic names the requirement to avoid cross contamination in the EU GMP Guideline, which has not been added to the PIC/S guidelines, yet.
Please also see the original announcement entitled "Procedure for discrepancies between EU and PIC/S GMP".
Related GMP News
08.04.2026Deficiencies in Equipment Design lead to Warning Letter
01.04.2026Rouging in pharmaceutical Water and Pure Steam Systems: Causes, Effects and Control Measures
18.03.2026HVAC Systems: Is there a Difference between Mixed Air and Recirculation Air Operation?
04.03.2026Warning Letter to US Contract Manufacturer of OTC Drugs due to Cross-Contamination Risk
04.03.2026Warning Letter following Complaints about Tablets
04.03.2026What does the FDA expect regarding Facility Maintenance?


